Neurotech is a privately held biotechnology company developing sight-saving therapeutics for chronic retinal diseases—including indications with significant unmet medical need that, as a whole, represent the largest market opportunity in ophthalmology. The Company is developing NT-501 to treat geographic atrophy (GA) associated with atrophic (dry) age-related macular degeneration (AMD) and retinitis pigmentosa (RP) and NT-503 to treat wet AMD. Neurotech's NT-501 product candidate is currently being studied in two Phase 2 trials to treat vision loss associated with RP and one Phase 2 trial to treat GA—a serious sight-threatening condition involving an advanced stage of dry AMD. NT-501 received Orphan Drug Status for the treatment of RP and Fast Track designation for the treatment of RP and dry AMD from the Food and Drug Administration.

The Company's NT-503 product candidate is in pre-clinical development and will address the need for better controlled and more convenient delivery of a VEGF antagonist for the treatment of neovascular (wet) AMD.

Neurotech's patented core technology platform, Encapsulated Cell Technology (ECT), enables the controlled, continuous delivery of proprietary therapeutic factors directly to the retina, bypassing the blood-retinal barrier and overcoming a major obstacle in the treatment of retinal diseases. Conventional approaches to therapy are limited by the absence of an acceptable means of sustained protein delivery across the blood-retinal barrier. While therapeutic agents can be injected directly into the eye, this is an impractical approach if regular administration is required. Neurotech's ECT implants are semi-permeable, hollow fiber membranes that encapsulate genetically modified cells that produce a specific therapeutic protein. Long-term protein delivery (up to 24 months) to the back of the eye and retina has been demonstrated in recent clinical studies, thereby confirming the long-term cell viability of ECT.